» Articles » PMID: 30205700

Isoform-specific Activities of the Regulatory Subunits of Phosphatidylinositol 3-kinases - Potentially Novel Therapeutic Targets

Overview
Publisher Informa Healthcare
Specialty Pharmacology
Date 2018 Sep 13
PMID 30205700
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

The main regulatory subunits of Class IA phosphatidylinositol 3-kinase (PI3K), p85α and p85β, initiate diverse cellular activities independent of binding to the catalytic subunit p110. Several of these signaling processes directly or indirectly contribute to a regulation of PI3K and could become targets for therapeutic efforts. Areas covered: This review will highlight two general areas of p85 activity: (1) direct interaction with regulatory proteins and with determinants of the cytoskeleton, and (2) a genetic analysis by deletion and domain switches identifying new functions for p85 domains. Expert Opinion: Isoform-specific activities of regulatory subunits have long been at the periphery of the PI3K field. Our understanding of these unique functions of the regulatory subunits is fragmentary and raises many important questions. At this time, there is insufficient information to translate this knowledge into the clinic, but some tempting targets have emerged that could move the field forward with the help of novel technologies in drug design and identification.

Citing Articles

Improved production of class I phosphatidylinositol 4,5-bisphosphate 3-kinase.

Messing S, Widmeyer S, Denson J, Mehalko J, Wall V, Drew M Protein Expr Purif. 2024; 225:106582.

PMID: 39173964 PMC: 11421577. DOI: 10.1016/j.pep.2024.106582.


Therapeutic Role of Synthetic Lethality in -Deficient Malignancies.

Hein K, Stephen B, Fu S J Immunother Precis Oncol. 2024; 7(1):41-52.

PMID: 38327752 PMC: 10846636. DOI: 10.36401/JIPO-22-37.


Mechanistic target of rapamycin (mTOR): a potential new therapeutic target for rheumatoid arthritis.

Zhang F, Cheng T, Zhang S Arthritis Res Ther. 2023; 25(1):187.

PMID: 37784141 PMC: 10544394. DOI: 10.1186/s13075-023-03181-w.


New Targets and Strategies for Rheumatoid Arthritis: From Signal Transduction to Epigenetic Aspect.

Zhu M, Ding Q, Lin Z, Fu R, Zhang F, Li Z Biomolecules. 2023; 13(5).

PMID: 37238636 PMC: 10216079. DOI: 10.3390/biom13050766.


Involvement of PI3K/Akt signaling pathway in promoting osteogenesis on titanium implant surfaces modified with novel non-thermal atmospheric plasma.

Zheng Z, He Y, Long L, Gan S, Chen S, Zhang M Front Bioeng Biotechnol. 2022; 10:975840.

PMID: 36185461 PMC: 9523010. DOI: 10.3389/fbioe.2022.975840.


References
1.
Yu X, Li Z, Shen J . BRD7: a novel tumor suppressor gene in different cancers. Am J Transl Res. 2016; 8(2):742-8. PMC: 4846923. View

2.
Vadas O, Burke J, Zhang X, Berndt A, Williams R . Structural basis for activation and inhibition of class I phosphoinositide 3-kinases. Sci Signal. 2011; 4(195):re2. DOI: 10.1126/scisignal.2002165. View

3.
Roberts A, Davids M, Pagel J, Kahl B, Puvvada S, Gerecitano J . Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2015; 374(4):311-22. PMC: 7107002. DOI: 10.1056/NEJMoa1513257. View

4.
Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B . The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol. 2010; 11(5):329-41. DOI: 10.1038/nrm2882. View

5.
Wymann M, Pirola L . Structure and function of phosphoinositide 3-kinases. Biochim Biophys Acta. 1998; 1436(1-2):127-50. DOI: 10.1016/s0005-2760(98)00139-8. View